Clinical Trial Update: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating azacytidine, bendamustine, and piamprizumab in refractory/relapsed B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• azacytidine (azacitidine)
• piamprizumab (piamprizumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 1, Phase 2 | Status: UNKNOWN